文献速递中医内科中药与中成药合理使用

中草药治疗抑郁症的系统评价与网状Meta分析

Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis.
PubMed 文献 · Front Pharmacol · 2024-04-03

该研究采用贝叶斯网状Meta分析,评估中草药治疗抑郁症的疗效与安全性。共纳入198项RCT、8923例患者,涉及17种中草药;部分中草药在应答率和HAMD减分上优于常用合成药,且不良事件风险更低,但需更大样本高质量试验验证。

要点

  • 归脾丸、逍遥丸等中草药在抑郁应答率或HAMD减分上可能优于部分合成药。
  • 部分中草药的不良事件风险低于氟西汀等常用抗抑郁合成药。
  • 结论需更大样本、方法学更稳健的试验进一步验证。

核心结论

  • 中草药作为抑郁症替代治疗具有前景,部分中草药疗效与安全性优于常用合成药。
  • 研究结果支持将中草药整合入现代抑郁症管理,但需更大规模高质量试验验证。

研究设计与样本

  • 贝叶斯网状Meta分析,检索PubMed、万方、EMBASE、CNKI和Cochrane Library及灰色文献至2023年7月底。
  • 共纳入198项RCT、8923例患者,评估17种中草药,采用马尔可夫链蒙特卡洛方法进行直接与间接比较。

主要发现

  • 应答率排名前三可能为归脾丸、Ease Pill和柴胡加龙骨牡蛎汤。
  • HAMD减分排名前三为柴胡疏肝散、醒脑解郁汤和逍遥散。
  • 不良事件率最低前三为逍遥散、阿普唑仑和醒脑解郁汤。
  • 常用合成药(氟西汀、艾司西酞普兰、阿米替林、舍曲林、氟哌噻吨美利曲辛和文拉法辛)疗效可能低于特定中草药,且不良事件风险更高。

关键数值与推荐

  • 应答率、HAMD评分和不良事件率通过直接与间接比较评估,效应量以OR及95%CI表示。
  • SUCRA结果显示归脾丸、Ease Pill、柴胡加龙骨牡蛎汤应答率排名前三。
  • 柴胡疏肝散、醒脑解郁汤、逍遥散HAMD减分排名前三。
  • 逍遥散、阿普唑仑、醒脑解郁汤不良事件率最低排名前三。

临床怎么用

  • 临床可参考网状Meta分析排序,结合辨证选用归脾丸、逍遥散、柴胡疏肝散等中草药治疗抑郁症。
  • 对常用合成药不耐受或不良事件风险高的患者,可考虑特定中草药替代,但需监测疗效与安全性。

局限性

  • 结论为初步发现,需更大样本、方法学更稳健的试验进一步验证和修正。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: Amidst rising global burden of depression and the associated challenges with conventional antidepressant therapies, there is a growing interest in exploring the efficacy and safety of alternative treatments. This study uses a Bayesian network meta-analysis to rigorously evaluate the therapeutic potential of Chinese herbal medicines in the treatment of depression, focusing on their comparative efficacy and safety against standard pharmacological interventions. Methods: Five databases (PubMed, Wanfang Data, EMBASE, CNKI, and the Cochrane Library) and grey literature were searched from inception to end of July 2023 to identify studies that assessed the efficacy and safety of Chinese herbal medicines in treating depression. The response rate, Hamilton Depression Scale (HAMD) scores, and rates of adverse events were assessed through both direct and indirect comparisons. Data extraction and risk of bias assessment were meticulously performed. Statistical analysis used Markov chain Monte Carlo methods, with effect size estimates provided as odd ratios and their 95% confidence intervals. Results: A total of 198 RCTs involving 8,923 patients were analyzed, assessing 17 Chinese herbal medicines. Surface Under the Cumulative Ranking results indicated that the top three treatments with the best response rate were possibly Guipiwan, Ease Pill, and Chaihu Jia Longgu Muli Decoction; the top three treatments on the reduction of HAMD scores were Chai Hu Shu Gan San, Xingnao Jieyu Decoction, and Xiaoyao Powder; and the top three treatments with the lowest adverse effects rates were Xiaoyao Powder, Alprazolam, and Xingnao Jieyu Decoction. Interestingly, commonly used synthetic drugs such as Fluoxetine, Escitalopram, Amitriptyline, Sertraline, Flupentixol and Melitracen, and Venlafaxine, not only appeared to be less effective than specific Chinese herbal medicines (Gan Mai Da Zao Decoction, Chaihu Jia Longgu Muli Decoction, Chai Hu Shu Gan San, Danzhi-Xiaoyao-San, and Xingnao Jieyu Decoction), but they were also related to substantially higher risk of adverse events. Conclusion: Our findings elucidate the promising therapeutic potential of Chinese herbal medicines as viable alternatives in the treatment of depression, with certain herbs demonstrating enhanced efficacy and safety profiles. The outcomes of this study advocate for the integration of these alternative modalities into contemporary depression management paradigms. However, it underscores the necessity for larger, methodologically robust trials to further validate and refine these preliminary findings. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023452109.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Dang C, Wang Q, Li Q, et al. Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis. Front Pharmacol. 2024. PMID: 38633609. doi:10.3389/fphar.2024.1295564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。